ArticleBlood cancer journal2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Yucai Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.